BioSpace News Archive

ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that the National and Kapodistrian University of Athens has published results of a new study undertaken in non-small cell lung cancer.

Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization of mammalian, microbial and gene therapy biologics, announces its first webinar of the 2021 series: Regulatory Strategies for Gene Therapy Product Development.

Targets for 2021 include dermal injector commercial launch, new partnerships, new innovation initiatives, and launch of more clinical testing

HEXO Corp (“HEXO”, or the “Company”) (TSX: HEXO; NYSE: HEXO) announced today that it has appointed Charles Bowman as General Manager of its US operations, effective immediately.

NovaBay Pharmaceuticals enters 2021 focused on growing sales of our high-quality, differentiated consumer products: Avenova®, the premier antimicrobial lid and lash spray, and CelleRx® Clinical Reset, a breakthrough product that marked our entry into a new beauty category late last year.

- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal quarter ended December 31, 2020 on Thursday, February 11, 2021 at 4:30 pm ET

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced today the peer-reviewed journal Psychiatry Research has published a new analysis showing the combinatorial approach available in the GeneSight® Psychotropic test is better than single-gene testing at predicting patient outcomes and medication blood levels.

Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for PBKR03,

OpSens Inc. (“OpSens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) today announced that OpSens Solutions Inc. (“OpSens Solutions”), its wholly-owned subsidiary focused on applying the Company’s proprietary and innovative fiber optic measurement solutions to industrial applications, has been awarded a contract from RI Research Instruments GmbH

Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, today announced that the Company’s Board of Directors (the “Board”) has elected Dr. Dale Chappell, the Company’s chief scientific officer, to serve as a director of the Company, effective February 5, 2021.